VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IARTIntegra LifeSciences Holdings Corporation
$18.76$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIARTFinancials

Integra LifeSciences Holdings Corporation (IART) Financials

30Y historyFree accessUpdated daily

Revenue growth remains inconsistent at 2.4% in 2026Q1, while gross margins have compressed significantly from 57.0% in 2023Q4 to 49.5% by 2025Q4.

IART Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue1.64B1.64B1.61B1.54B1.56B1.54B1.37B1.52B1.47B1.19B992.08M882.73M928.3M836.21M830.87M780.08M732.07M682.49M654.6M550.46M419.3M277.94M229.82M185.6M112.63M93.44M64.99M42.5M17.5M14.7M13.1M
Revenue Growth %1.24%1.53%4.47%-1.03%0.99%12.43%-9.6%3.06%23.92%19.77%12.39%-4.91%11.01%0.64%6.51%6.56%7.26%4.26%18.92%31.28%50.86%20.93%23.83%64.79%20.53%43.79%52.91%142.86%19.05%12.21%28.43%
Cost of Goods Sold601.79M790.01M728.47M656.84M587.36M597.81M520.83M564.68M571.5M435.51M349.09M326.54M352.8M334.08M314.43M299.15M268.19M244.92M252.83M214.67M168.31M105.54M87.3M70.6M45.77M36.01M26.82M21.8M6.1M5.2M4.7M
COGS % of Revenue-48.31%45.23%42.61%37.71%38.76%37.97%37.21%38.81%36.65%35.19%36.99%38%39.95%37.84%38.35%36.63%35.89%38.62%39%40.14%37.97%37.98%38.04%40.64%38.54%41.26%51.29%34.86%35.37%35.88%
Gross Profit650.8M845.23M882.06M884.74M970.31M944.64M851.03M952.88M900.95M752.73M642.99M556.19M575.5M502.13M516.44M480.93M463.88M437.57M401.78M335.79M250.98M172.4M142.53M115M66.85M57.43M38.17M20.7M11.4M9.5M8.4M
Gross Margin %39.57%51.69%54.77%57.39%62.29%61.24%62.03%62.79%61.19%63.35%64.81%63.01%62%60.05%62.16%61.65%63.37%64.11%61.38%61%59.86%62.03%62.02%61.96%59.36%61.46%58.74%48.71%65.14%64.63%64.12%
Gross Profit Growth %--4.18%-0.3%-8.82%2.72%11%-10.69%5.76%19.69%17.07%15.6%-3.36%14.61%-2.77%7.38%3.68%6.01%8.91%19.65%33.79%45.58%20.96%23.93%72.02%16.41%50.45%84.4%81.58%20%13.1%25.37%
Operating Expenses768.72M776.92M853.65M773.21M731.39M747.41M699.66M859.12M789.95M707.92M527.65M476.61M509.96M459.04M442.66M426.02M365.19M339.75M354.37M268.5M192.24M116.29M117.75M75.36M45.34M43.14M56.55M33.1M25.5M28.5M17.9M
OpEx % of Revenue-47.51%53%50.16%46.95%48.46%51%56.61%53.65%59.58%53.19%53.99%54.93%54.89%53.28%54.61%49.88%49.78%54.13%48.78%45.85%41.84%51.23%40.6%40.26%46.17%87.02%77.88%145.71%193.88%136.64%
Selling, General & Admin696.44M699.7M716.98M656.64M616.32M637.45M594.53M687.6M690.75M624.1M455.63M415.76M445.97M394.25M373.11M358.13M305.06M281.1M281M225.19M157.71M98.27M99.36M59.46M40.59M32.37M43.85M22.2M15.8M20.3M9.6M
SG&A % of Revenue-42.79%44.52%42.6%39.57%41.33%43.34%45.31%46.91%52.52%45.93%47.1%48.04%47.15%44.91%45.91%41.67%41.19%42.93%40.91%37.61%35.36%43.23%32.04%36.04%34.64%67.48%52.24%90.29%138.1%73.28%
Research & Development97.75M98.97M115.38M104.19M101.19M93.05M77.38M79.57M78.04M63.45M58.16M50.9M51.6M52.09M51.01M51.45M48.11M44.28M60.49M30.66M25.73M11.96M14.12M12.81M8.3M7.99M7.52M8.7M8.4M6.4M6.3M
R&D % of Revenue-6.05%7.16%6.76%6.5%6.03%5.64%5.24%5.3%5.34%5.86%5.77%5.56%6.23%6.14%6.6%6.57%6.49%9.24%5.57%6.14%4.3%6.14%6.9%7.37%8.55%11.58%20.47%48%43.54%48.09%
Other Operating Expenses-1000K-21.75M21.29M12.38M13.88M16.91M27.76M91.94M8.29M1.34M845K4.59M-763K-1.8M-721K16.43M12.02M14.36M12.88M12.65M8.8M6.06M4.27M3.08M-3.55M2.78M5.18M2.2M1.3M1.8M2M
Operating Income95.28M68.32M28.41M111.53M238.92M197.23M151.37M93.76M111M44.8M115.34M79.59M65.54M-3.64M73.78M54.91M98.69M97.82M47.41M67.29M58.74M56.1M24.78M39.65M19.19M14.29M-18.38M-12.4M-14.1M-19M-9.5M
Operating Margin %5.79%4.18%1.76%7.23%15.34%12.79%11.03%6.18%7.54%3.77%11.63%9.02%7.06%-0.44%8.88%7.04%13.48%14.33%7.24%12.22%14.01%20.19%10.78%21.36%17.04%15.29%-28.29%-29.18%-80.57%-129.25%-72.52%
Operating Income Growth %-140.46%-74.53%-53.32%21.14%30.3%61.44%-15.53%147.74%-61.15%44.92%21.43%1898.6%-104.94%34.36%-44.36%0.89%106.33%-29.54%14.54%4.7%126.42%-37.5%106.63%34.31%177.71%-48.25%12.06%25.79%-100%-58.33%
EBITDA209.14M219.37M168.91M235.04M360.04M320.9M270.36M203.22M226.7M133.7M188M89.54M77.94M43.37M92.32M71.34M137.87M137.51M80.56M94.33M80.22M69.33M36.37M48.69M26.35M20.54M-13.21M-10.2M-12.8M-17.2M-7.5M
EBITDA Margin %12.72%13.41%10.49%15.25%23.11%20.8%19.71%13.39%15.4%11.25%18.95%10.14%8.4%5.19%11.11%9.15%18.83%20.15%12.31%17.14%19.13%24.94%15.83%26.23%23.4%21.98%-20.32%-24%-73.14%-117.01%-57.25%
EBITDA Growth %33.75%29.87%-28.13%-34.72%12.2%18.7%33.03%-10.36%69.55%-28.88%109.97%14.88%79.73%-53.03%29.4%-48.25%0.26%70.7%-14.6%17.58%15.72%90.61%-25.3%84.79%28.26%255.55%-29.48%20.31%25.58%-129.33%-63.04%
D&A (Non-Cash Add-back)113.86M151.05M140.5M123.51M121.11M123.67M118.99M109.46M115.7M88.9M72.67M9.95M12.4M47.01M18.54M16.43M39.17M39.69M33.15M27.04M21.48M13.22M11.59M9.04M7.16M6.26M5.18M2.2M1.3M1.8M2M
EBIT-466.03M-477.25M52.4M132.45M263.49M242.66M148.95M114.06M125.34M46.33M116.21M84.2M67.53M-6.94M74.27M56.13M100.47M96.38M48.62M67.29M58.74M56.1M24.78M39.65M21.52M14.29M-18.38M-15.21M-17.56M-19M-9.5M
Net Interest Income-53.39M-67.78M-50.59M-34.17M-37.68M-43.66M-62.28M-43.18M-61.88M-34.76M-25.78M-23.5M-21.8M-14.79M-21.03M-27.18M-18.13M-22.6M-27.97M000000000000
Interest Income18.16M18.47M20.04M17.2M11.92M6.74M9.3M10.78M2.8M255K24K13K168K4.93M1.21M465K225K631K2.11M000000000000
Interest Expense44.98M86.25M70.63M51.38M49.59M50.4M71.58M53.96M64.68M35.02M25.8M23.52M21.97M19.73M22.24M27.64M18.36M23.23M30.09M000000000000
Other Income/Expense-631.16M-631.82M-46.65M-30.46M-25.03M17.45M-57.85M-33.66M-53.59M-33.42M-24.93M-18.92M-24.88M-21.15M-21.75M-26.42M-16.58M-24.67M-16.41M-7.23M-10.44M-1M3.23M3.54M3.54M1.26M7.54M7.42M5.26M2M1.9M
Pretax Income-535.88M-563.5M-18.24M81.07M213.89M214.68M93.52M60.1M57.4M11.38M90.41M60.67M42.98M-24.79M52.03M28.49M82.11M73.15M31.01M60.06M48.31M55.1M28.01M43.19M22.73M15.54M-10.85M-7.8M-12.3M-17M-7.6M
Pretax Margin %-32.59%-34.46%-1.13%5.26%13.73%13.92%6.82%3.96%3.9%0.96%9.11%6.87%4.63%-2.96%6.26%3.65%11.22%10.72%4.74%10.91%11.52%19.83%12.19%23.27%20.18%16.63%-16.69%-18.35%-70.29%-115.65%-58.02%
Income Tax-40.08M-47.03M-11.29M13.33M33.34M45.6M-40.37M9.9M-3.4M-53.36M15.84M53.82M8.97M-7.81M10.82M505K16.45M22.2M-3.93M26.59M18.9M17.91M10.81M16.33M-12.55M-10.86M108K-1.8M-1.8M0-2M
Effective Tax Rate %7.48%8.35%61.92%16.44%15.59%21.24%-43.17%16.48%-5.92%-468.67%17.52%88.71%20.88%31.52%20.81%1.77%20.03%30.34%-12.67%44.27%39.13%32.5%38.6%37.81%-55.23%-69.89%-1%23.08%14.63%0%26.32%
Net Income-495.8M-516.47M-6.94M67.74M180.55M169.07M133.89M50.2M60.8M64.74M74.56M-3.52M34M-16.98M41.2M27.99M65.67M50.95M34.93M33.47M29.41M37.19M17.2M26.86M35.28M26.16M-11.43M-6M-12.3M-17M-7.5M
Net Margin %-30.15%-31.58%-0.43%4.39%11.59%10.96%9.76%3.31%4.13%5.45%7.52%-0.4%3.66%-2.03%4.96%3.59%8.97%7.47%5.34%6.08%7.01%13.38%7.48%14.47%31.32%28%-17.58%-14.12%-70.29%-115.65%-57.25%
Net Income Growth %-1612.31%-7337.7%-110.25%-62.48%6.79%26.28%166.71%-17.43%-6.09%-13.17%2218.9%-110.35%300.29%-141.2%47.22%-57.38%28.88%45.86%4.37%13.82%-20.94%116.28%-35.98%-23.86%34.84%329%-90.42%51.22%27.65%-126.67%70.47%
Net Income (Continuing)-495.8M-516.47M-6.94M67.74M180.55M169.07M133.89M50.2M60.8M64.74M74.56M6.85M36.3M22.03M41.2M27.99M65.67M50.95M34.93M33.47M29.41M37.19M17.2M26.86M35.28M26.41M-10.96M-5.97M-12.34M-17M-7.5M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)-6.44-6.73-0.090.842.161.981.570.580.720.820.94-0.050.52-0.290.720.481.090.870.480.560.490.570.280.430.570.47-0.33-0.18-0.38-0.58-0.27
EPS Growth %-1605.95%-7361.2%-110.74%-61.11%9.09%26.11%170.69%-19.44%-12.2%-12.77%2074.79%-109.15%279.31%-140.28%50%-55.96%25.29%81.25%-14.29%14.29%-14.04%103.57%-34.88%-24.56%21.28%242.42%-83.33%52.63%34.48%-114.81%77.69%
EPS (Basic)--6.73-0.090.872.182.001.580.590.730.831.00-0.050.52-0.300.740.521.110.880.490.610.500.620.280.460.610.54-0.33-0.18-0.38-0.58-0.27
Diluted Shares Outstanding76.95M76.75M77.01M80.34M83.52M85.48M85.23M86.49M84.45M79.12M79.19M73.88M65.92M57.6M57.03M58.99M60.3M58.58M56.76M59.16M65.49M69.13M62.2M66.21M61.79M55.59M35.11M34.12M32.28M29.57M28.11M
Basic Shares Outstanding76.95M76.75M77.01M78.17M83M84.7M84.65M85.64M82.86M78.39M74.72M73.88M65.48M56.83M55.9M53.66M59.1M58.08M55.56M55.42M58.6M60.39M60.13M58.14M58.04M46.71M35.11M33.6M32.28M29.57M28.11M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowDeteriorating
Top Statement Risk

Manufacturing and regulatory remediation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Stagnant Revenue Growth Amid Volatility

As reported in recent financial filings, Integra's revenue growth has remained inconsistent, with a 2.4% year-over-year increase in 2026Q1 following a period of erratic quarterly performance, suggesting that the company is struggling to achieve sustained top-line momentum in its core neurosurgery and tissue technology segments.

The lack of consistent revenue expansion appears to reflect ongoing supply chain constraints and potential market share erosion in the competitive wound care space. Investors should monitor whether the company can stabilize its product delivery timelines, as current growth rates remain insufficient to offset the high fixed-cost burden inherent in its manufacturing operations.

Structural Margin Compression and Instability

Based on the provided income statement data, gross margins have fluctuated significantly, dropping from 57.0% in 2023Q4 to 49.5% by 2025Q4, which indicates that the company is facing persistent pricing pressure or rising production costs that are eroding its core profitability profile.

The volatility in gross margins suggests that Integra lacks the pricing power to fully pass on inflationary costs to hospital systems, particularly within its commoditized surgical instrument lines. This margin instability complicates the path to profitability, as the company requires consistent gross profit generation to cover its substantial administrative and R&D overhead.

Operating Leverage Impaired by Costs

According to the company's historical income statements, operating leverage has been severely compromised, with operating margins swinging from positive territory to a deep -123.4% in 2025Q2, highlighting an inability to scale operating income effectively against a rigid and increasingly expensive cost structure.

The erratic nature of operating income suggests that the company is frequently burdened by non-recurring charges, likely related to manufacturing remediation and quality control failures. This lack of operating discipline implies that management has yet to successfully decouple revenue growth from the rising costs of maintaining its specialized biological manufacturing facilities.

Earnings Quality Obscured by Impairments

As evidenced by the reported net income figures, which include a massive loss of $484.1 million in 2025Q2, the quality of earnings appears poor, with frequent non-operating charges and impairment events masking the underlying cash-generative potential of the Codman neurosurgery franchise.

The wide gap between operational performance and bottom-line results suggests that investors should be wary of relying on GAAP net income as a proxy for business health. The recurring nature of these large, negative adjustments warrants further investigation into whether these are truly one-time events or symptomatic of deeper, systemic operational inefficiencies.

Terminal Risk in Manufacturing Infrastructure

Based on the persistent manufacturing quality issues highlighted in recent filings, the primary risk to the investment thesis is that the company's aging production infrastructure may require capital expenditures far exceeding current projections, potentially leading to long-term margin dilution and loss of market relevance.

Short-sellers would likely focus on the company's inability to resolve site-specific recalls, which threatens the 'standard of care' status of key products like DuraGen. If these operational lapses continue, the company may face a permanent impairment of its competitive moat, regardless of the strength of its underlying collagen-based intellectual property.

IART — Frequently Asked Questions

Quick answers to the most common questions about buying IART stock.

What was Integra LifeSciences Holdings Corporation's (IART) revenue in 2025?

For fiscal year 2025, Integra LifeSciences Holdings Corporation (IART) reported total revenue of $1.64B. This represents a 12382.8% increase compared to $13.1M in 1996.

Is Integra LifeSciences Holdings Corporation (IART) profitable?

Integra LifeSciences Holdings Corporation (IART) reported a net loss of $516.5M for the fiscal year ending 2025.

What is Integra LifeSciences Holdings Corporation's operating profit margin?

Integra LifeSciences Holdings Corporation (IART) reported an operating income of $68.3M, resulting in an operating profit margin of 4.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Integra LifeSciences Holdings Corporation's gross profit and gross margin?

Integra LifeSciences Holdings Corporation (IART) generated $845.2M in gross profit for the year, representing a gross profit margin of 51.7%. This demonstrates the company's core pricing power and production efficiency.